Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (22)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Edell, D.
Right arrow Articles by Salter, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Edell, D.
Right arrow Articles by Salter, K.
(Chest. 2002;122:935-939.)
© 2002 American College of Chest Physicians

Early Ribavarin Treatment of Bronchiolitis*

Effect on Long-term Respiratory Morbidity

Dean Edell, MD, MPH; Vikram Khoshoo, MD, PhD; Gerald Ross, MD and Karen Salter, RN

* From West Jefferson Medical Center, New Orleans, LA.

Correspondence to: Dean Edell, MD, MPH, West Jefferson Medical Center, 1111 Medical Center Blvd, S 650, Marrero, LA 70072

Background: The mortality rate from respiratory syncytial virus (RSV) bronchiolitis has significantly reduced over the last decade. A major concern now is the long-term respiratory morbidity following RSV bronchiolitis.

Methods: In this prospective study, we randomly assigned 49 previously healthy infants with severe RSV bronchiolitis, early in the course of illness (< 5 days duration), to receive either conservative treatment (n = 21) or additional ribavirin treatment (n = 24). Both groups were closely matched for age and clinical characteristics.

Results: During a prospective, closely monitored, 1-year follow-up period, the group treated with ribavirin had significantly fewer episodes (2.7 ± 2.3 episodes vs 6.4 ± 4.2 episodes per patient per year) and reduced severity of reactive airway disease (0.08 episodes vs 1.09 episodes of moderate-to-severe illness per patient per year) and respiratory illness-related hospitalization (25 hospital days vs 90 hospital days per 100 patients per year).

Conclusions: Early ribavirin treatment of RSV bronchiolitis in previously healthy infants resulted in reduction of incidence and severity of reactive airway disease as well as respiratory illness-related hospitalization.

Key Words: bronchiolitis • reactive airway disease • respiratory syncytial virus • ribavirin




This article has been cited by other articles:


Home page
 PediatricsHome page
Subcommittee on Diagnosis and Management of Bronch
Diagnosis and Management of Bronchiolitis
Pediatrics, October 1, 2006; 118(4): 1774 - 1793.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
A. J. Easton, J. B. Domachowske, and H. F. Rosenberg
Animal Pneumoviruses: Molecular Genetics and Pathogenesis
Clin. Microbiol. Rev., April 1, 2004; 17(2): 390 - 412.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
V. J. King, M. Viswanathan, W. C. Bordley, A. M. Jackman, S. F. Sutton, K. N. Lohr, and T. S. Carey
Pharmacologic Treatment of Bronchiolitis in Infants and Children: A Systematic Review
Arch Pediatr Adolesc Med, February 1, 2004; 158(2): 127 - 137.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American College of Chest Physicians.